A CR-UK phase I dose escalation study of BKM120 in patients with non-small cell lung cancer (NSCLC) receiving thoracic radiotherapy

Trial Profile

A CR-UK phase I dose escalation study of BKM120 in patients with non-small cell lung cancer (NSCLC) receiving thoracic radiotherapy

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Oct 2017

At a glance

  • Drugs Buparlisib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 29 Sep 2017 Status changed from recruiting to active, no longer recruiting.
    • 10 Jun 2017 Biomarkers information updated
    • 02 Mar 2017 Planned End Date changed from 1 Mar 2017 to 31 Mar 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top